Full Bril­in­ta study re­sults show the blood thin­ner re­duces rate of sec­ondary stroke

As­traZeneca once pro­ject­ed its Bril­in­ta drug to peak at $3.5 bil­lion in sales, and though the blood thin­ner nev­er reached that lofty goal, it re­ceived the lat­est pos­i­tive signs in a string of re­cent good news.

The phar­ma re­leased full de­tails from its THALES study Thurs­day morn­ing, which mea­sured the ef­fects of Bril­in­ta and as­pirin against as­pirin alone in treat­ing pa­tients who had an acute is­chemic stroke or tran­sient is­chemic at­tack. When tak­en twice dai­ly with once-a-day as­pirin for 30 days, the Bril­in­ta com­bo re­duced the risk of stroke and death by 17 per­cent, meet­ing the pri­ma­ry end­point of the study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.